Tags |
|
|
Links |
|
|
Advice Pool - Alzheimer's Tests Determine Mental Agility
Alois Alzheimer, the doctor who first described Alzheimer's disease in 1906, would be appalled to learn that over 100 years later there is still no cure for this dreaded bra
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
in disease.
The brain destroying properties of Alzheimer’s disease are still as much a mystery today as they were over 100 years ago.
There are several advanced tests tha
The brain destroying properties of Alzheimer’s disease are still as much a mystery today as they were over 100 years ago.
There are several advanced tests tha
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
t display a loss of mental agility. A trained doctor can determine with some accuracy whether a person has this dreaded affliction. The diagnosis of Alzheimer’s today is s
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
ill a death sentence. Those plaques and tangles in the brain are not discovered until an autopsy is performed.
The tests that are conducted on Alzheimer's patients can dete
The tests that are conducted on Alzheimer's patients can dete
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
rmine the severity of the disease but these test can not determine the cause for Alzheimer’s nor can they offer any clues as to how to defeat this disease.
What the test wi
What the test wi
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
l determine is the stage of brain deterioration. What will be evident is that Alzheimer’s has destroyed a person’s memory and will eventually rid them of their ability to
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
function. The person with Alzheimer’s is left without the ability to learn or reason. The Alzheimer patient loses the ability to make judgments or engage in any type commu
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
ication.
The diagnostic tests and tools will determine whether a person has Alzheimer’s disease. Specialist in neurology or a Geriatric Specialist do not use brain scans o
The diagnostic tests and tools will determine whether a person has Alzheimer’s disease. Specialist in neurology or a Geriatric Specialist do not use brain scans o
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
r invasive procedures to determine the validity of an Alzheimer’s diagnosis.
The brain is the most critical organ of the body and also the most difficult to navigate for an
The brain is the most critical organ of the body and also the most difficult to navigate for an
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
type of testing or screening to determin a disease or disorder. In fact in the case of Alzheimer’s the loss of memory or other behavioral symptoms are the major indicator
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
that there may be something wrong.
When these symptoms appear, the patient is usually in the latter stages of the disease and at this stage there is little hope of recover
When these symptoms appear, the patient is usually in the latter stages of the disease and at this stage there is little hope of recover
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
y.
There is still some validity in early detection of the disease. Some of the diagnosis tests given to patients to cnfirm a diagnose of Alzheimer's Disease include:
1)
There is still some validity in early detection of the disease. Some of the diagnosis tests given to patients to cnfirm a diagnose of Alzheimer's Disease include:
1)
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
A clock drawing test. - The patient is asked to draw a clock and to put the
numbers in their appropriate locations on the face of a clock.. The patient is then in
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
structed to draw specific hours on the clock, i.e. 3:00 or 11:15.
2) Mini-Mental State Examination (MMSE) - The MMSE is a brief test that measures the cognitive s
2) Mini-Mental State Examination (MMSE) - The MMSE is a brief test that measures the cognitive s
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
atus in adults.
3) Functional Assessment Staging (FAST) involves a checklist of functions required to evaluate the changes in functional performance and activities
3) Functional Assessment Staging (FAST) involves a checklist of functions required to evaluate the changes in functional performance and activities
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
of daily living
The person providing the test will check "Yes" if a characteristic is present. If the problem is due to other causes apart from dementia (i.e., arthritis,
The person providing the test will check "Yes" if a characteristic is present. If the problem is due to other causes apart from dementia (i.e., arthritis,
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
aralysis, etc.), the test provider will check "No". The test provider is required to note the results of each activity.
4) CANTAB-PAL's The PAL test is the newest A
4) CANTAB-PAL's The PAL test is the newest A
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
lzheimer’s mental agility test. This test is said to have a specific sensitivity to individuals with Alzheimer's disease. The test takes only 10 minutes and boasts a rate
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
of 98 percent accuracy.
The information from these tests is important to the patient as well as the family. Early diagnosis is important for the effective treatment of Al
The information from these tests is important to the patient as well as the family. Early diagnosis is important for the effective treatment of Al
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
zheimer's Disease. This information will be used by physicians to determine a course of action.
================================================================
================================================================
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.advicepool.org.ua/article/241827/advicepool-Alzheimers-Tests-Determine-Mental-Agility.html">Alzheimer's Tests Determine Mental Agility</a>
BB link (for phorums):
[url=http://www.advicepool.org.ua/article/241827/advicepool-Alzheimers-Tests-Determine-Mental-Agility.html]Alzheimer's Tests Determine Mental Agility[/url]
Related Articles:
Google Sitemaps for Newbies and Professionals
Ezine Article Writers - What is in Your Wallet?
Samsung Mobiles: Let Loose Your Passions
Bookmark it:
|